Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Phc Corporation has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 4 distinct art units, indicating separate examiner assignments with some art-unit concentration. The examiner count matches the office-action count, so each pending matter has a distinct examiner in the supplied data.
WHATLEY, BENJAMIN R is the busiest examiner, with 1 pending matter. Counsel should coordinate recurring technical issues at the art-unit level while retaining examiner-specific response strategies for each matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHATLEY, BENJAMIN R | 1 | 66.7% | +68.3% |
| GIERE, REBECCA M | 1 | 73.7% | +32.3% |
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
| COUNTS, GARY W | 1 | 58.9% | +29.7% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | REDDIG, PETER J | 15d overdue |
| 18821399 | CULTURE DEVICE | WHATLEY, BENJAMIN R | — |
| 18713773 | METHOD FOR MEASURING ELASTASE 1 IN FECES | GIERE, REBECCA M | — |
| 18575425 | BIOMARKER FOR DETECTING TUBULOINTERSTITIAL DISORDER AND USE THEREOF | DUNN, MCKENZIE A | — |
| 18565258 | METHOD FOR ASSESSING RISK OF HEMORRHAGIC STROKE USING SOLUBLE CLEC2 | COUNTS, GARY W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | REDDIG, PETER J | 15d overdue |
| 18821399 | CULTURE DEVICE | WHATLEY, BENJAMIN R | — |
| 18713773 | METHOD FOR MEASURING ELASTASE 1 IN FECES | GIERE, REBECCA M | — |
| 18575425 | BIOMARKER FOR DETECTING TUBULOINTERSTITIAL DISORDER AND USE THEREOF | DUNN, MCKENZIE A | — |
| 18565258 | METHOD FOR ASSESSING RISK OF HEMORRHAGIC STROKE USING SOLUBLE CLEC2 | COUNTS, GARY W | — |
| Art Unit | Apps |
|---|---|
| 1678 | 2 |
| 1798 | 1 |
| 1677 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18821399 | CULTURE DEVICE | WHATLEY, BENJAMIN R | 1798 | §102§103§112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18713773 | METHOD FOR MEASURING ELASTASE 1 IN FECES | GIERE, REBECCA M | 1677 | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18575425 | BIOMARKER FOR DETECTING TUBULOINTERSTITIAL DISORDER AND USE THEREOF | DUNN, MCKENZIE A | 1678 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18565258 | METHOD FOR ASSESSING RISK OF HEMORRHAGIC STROKE USING SOLUBLE CLEC2 | COUNTS, GARY W | 1678 | §101§112 | Final Rejection | — | Pending | Nov 29, 2023 |
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | REDDIG, PETER J | 1646 | §101§112 | Final Rejection | 15d overdue | Pending | Jul 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPhc Corporation has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Benjamin R Whatley has the most, with 1 of Phc Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
